Herantis Pharma Announces Successful HER-096 Initial Results with Blood-Brain Barrier Penetration in Dogs
Herantis Pharma Plc Press release 28 Apr 2022 at 9:00 am EEST Herantis Pharma Plc (“Herantis”), an innovative biotech company developing new disease modifying therapies for Parkinson’s disease, today announced initial results of HER-096 blood-brain barrier (BBB) penetration in dogs. The results demonstrate that following a single subcutaneous administration of HER-096, the concentration of HER-096 measured from the cerebrospinal fluid (CSF) is within the pharmacologically active level. This result is aligned with previous data obtained from rats. These data show that